ArticleBMC ophthalmology2026
Safety profile of same-day bilateral intravitreal dexamethasone implantation for diabetic and uveitic macular edema: a single-center experience.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the safety of same-day bilateral intravitreal dexamethasone (DEX) implant administration in patients with bilateral diabetic macular edema (DME) and uveitic macular edema (UME).
methodsThis retrospective, single-center, consecutive case series included 190 eyes from 95 patients who received same-day, bilateral intravitreal DEX implants. A comprehensive ophthalmologic evaluation, including a slit-lamp examination, intraocular pressure (IOP) assessment using Goldmann applanation tonometry, fundus examination, and optical coherence tomography (OCT), was performed at baseline and during the follow-up. Central macular thickness (CMT) was recorded, and ocular adverse events (AEs) were reviewed. Elevated IOP was defined as an IOP value ≥ 25 mmHg at any visit.
resultsA total of 293 bilateral same-day DEX implant administrations (586 eyes) were performed, with a mean of 3.04 ± 3.02 implants per patient (median: 2; range: 1–17). Mean follow-up duration was 55.72 ± 38.86 months (median: 48; range: 1-156). Eighty patients (84.2%) had DME and 15 (15.8%) had UME. Prior ocular surgeries including phacoemulsification, pars plana vitrectomy and seton implant surgery were present in 85 eyes (44.7%). At baseline, 79 eyes (41.5%) were pseudophakic. Significant CMT improvement was observed in the right eye (from 529.73 ± 170.81 μm to 335.15 ± 136.04 μm) and the left eye (from 528.06 ± 149.79 μm to 357.89 ± 142.38 μm) at the last visit (p < 0.001 for both). Elevated IOP occurred in 7 eyes (3.6%) and was managed with topical therapy without the need for surgical intervention. Cataract progression necessitating surgery occurred in 41 eyes (21.6%). Vitreous hemorrhage was observed in 1 (0.5%) eye and retinal detachment developed in 3 (1.6%) eyes, while no cases of endophthalmitis were observed.
conclusionsSame-day intravitreal DEX implantation appears to be a safe and effective therapeutic option for both DME and UME, with a low incidence of ocular AEs. This approach has the potential to reduce the treatment burden and may enhance patient compliance.
trial registrationRetrospectively registered. The study followed the tenets of the Declaration of Helsinki, and it was approved by the local ethical committee (Non-Interventional Clinical Research Ethics Committee of Dokuz Eylül University, registration number: 2024/06 − 01).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.